Cargando…

Response to pioglitazone in non-alcoholic fatty liver disease patients with vs. without type 2 diabetes: A meta-analysis of randomized controlled trials

BACKGROUND: Pioglitazone is considered a potential therapy for non-alcoholic fatty liver disease (NAFLD). However, different effects of pioglitazone on NAFLD have been demonstrated in diabetic and non-diabetic patients. Herein, a meta-analysis of randomized, placebo-controlled trials was carried out...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Zeyu, Du, Huiqing, Zhao, Ying, Ren, Yadi, Ma, Cuihua, Chen, Hongyu, Li, Man, Tian, Jiageng, Xue, Caihong, Long, Guangfeng, Xu, Meidong, Jiang, Yong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10091905/ https://www.ncbi.nlm.nih.gov/pubmed/37065735 http://dx.doi.org/10.3389/fendo.2023.1111430

Ejemplares similares

Rapamycin Attenuates Anxiety and Depressive Behavior Induced by Helicobacter pylori in Association with Reduced Circulating Levels of Ghrelin
por: Tian, Jiageng, et al.
Publicado: (2022)

Changes in and the association of retinal blood perfusion and retinal nerves in diabetic patients without retinopathy
por: Hao, Jianchen, et al.
Publicado: (2023)

Pioglitazone for NAFLD Patients With Prediabetes or Type 2 Diabetes Mellitus: A Meta-Analysis
por: Lian, Jingxuan, et al.
Publicado: (2021)

Endotoxins and Non-Alcoholic Fatty Liver Disease
por: Kessoku, Takaomi, et al.
Publicado: (2021)

Corrigendum: Pioglitazone for NAFLD Patients With Prediabetes or Type 2 Diabetes Mellitus: A Meta-Analysis
por: Lian, Jingxuan, et al.
Publicado: (2022)

Stratified glucose-lowering response to vildagliptin and pioglitazone by obesity and hypertriglyceridemia in a randomized crossover trial
por: Brandon, Rebecca, et al.
Publicado: (2023)

ODP426 SPIOMET4HEALTH: a 4-Arm Trial to Test the Effects of Lifestyle Intervention plus either Placebo, or Pioglitazone (PIO), or Spironolactone-Pioglitazone (SPIO), or Spironolactone-Pioglitazone-Metformin (SPIOMET) in Adolescent Girls and Young Women with PCOS
por: Ibanez, Lourdes, et al.
Publicado: (2022)

Gut Dysfunction and Non-alcoholic Fatty Liver Disease
por: Grabherr, Felix, et al.
Publicado: (2019)

Oxidation-Specific Epitopes in Non-Alcoholic Fatty Liver Disease
por: Hendrikx, Tim, et al.
Publicado: (2020)

Determinants of hyperglucagonemia in pediatric non-alcoholic fatty liver disease
por: Maruszczak, Katharina, et al.
Publicado: (2022)

Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)
por: Rong, Li, et al.
Publicado: (2023)

Seabuckthorn polysaccharide combined with astragalus polysaccharide ameliorate alcoholic fatty liver by regulating intestinal flora
por: Liu, Jiayue, et al.
Publicado: (2022)

Anti-diabetic combination therapy with pioglitazone or glimepiride added to metformin on the AGE-RAGE axis: a randomized prospective study
por: Ragazzi, Eugenio, et al.
Publicado: (2023)

Effects of Bariatric Endoscopy on Non-Alcoholic Fatty Liver Disease: A Comprehensive Systematic Review and Meta-Analysis
por: Ren, Mengting, et al.
Publicado: (2022)

The Role of Lipophagy in the Development and Treatment of Non-Alcoholic Fatty Liver Disease
por: Grefhorst, Aldo, et al.
Publicado: (2021)

Autonomic Imbalance Increases the Risk for Non-alcoholic Fatty Liver Disease
por: Jung, Inha, et al.
Publicado: (2021)

Thyroid Function and the Risk of Non-Alcoholic Fatty Liver Disease in Morbid Obesity
por: Borges-Canha, Marta, et al.
Publicado: (2020)

Effects of scoparone on non-alcoholic fatty liver disease revealed by RNA sequencing
por: Huang, Xiaoyan, et al.
Publicado: (2022)

Non-alcoholic fatty liver disease across endocrinopathies: Interaction with sex hormones
por: Arefhosseini, Sara, et al.
Publicado: (2022)

Association between hemoglobin glycation index and non-alcoholic fatty liver disease
por: Xing, Yuling, et al.
Publicado: (2023)

Current insights in molecular characterization of non-alcoholic fatty liver disease and treatment
por: Che, Wensheng, et al.
Publicado: (2022)

Non-alcoholic fatty liver disease in type 1 diabetes: Prevalence and pathophysiology
por: Memaj, Plator, et al.
Publicado: (2022)

The change of non-alcoholic fatty liver disease is associated with risk of incident diabetes
por: Chen, Congling, et al.
Publicado: (2023)

Fatty liver index predicts incident risk of prediabetes, type 2 diabetes and non-alcoholic fatty liver disease (NAFLD)
por: Cuthbertson, Daniel J., et al.
Publicado: (2021)

Analysis of risk factors for non-alcoholic fatty liver disease in hospitalized children with obesity before the late puberty stage
por: Zhou, Lishan, et al.
Publicado: (2023)

Bariatric Surgery and Non-Alcoholic Fatty Liver Disease: Current and Potential Future Treatments
por: Sasaki, Akira, et al.
Publicado: (2014)

Single Point Insulin Sensitivity Estimator in Pediatric Non-Alcoholic Fatty Liver Disease
por: Furthner, Dieter, et al.
Publicado: (2022)

Non-Alcoholic Fatty Liver Disease and Hypokalemia in Primary Aldosteronism Among Chinese Population
por: Chen, Yi, et al.
Publicado: (2021)

Effects of sitagliptin on intrahepatic lipid content in patients with non-alcoholic fatty liver disease
por: Wang, Xingchun, et al.
Publicado: (2022)

Exercise intervention improves mitochondrial quality in non-alcoholic fatty liver disease zebrafish
por: Zou, Yun-Yi, et al.
Publicado: (2023)

Erratum: Non-alcoholic fatty liver disease in type 1 diabetes: Prevalence and pathophysiology
Publicado: (2023)

Impact of Porphyromonas gingivalis-odontogenic infection on the pathogenesis of non-alcoholic fatty liver disease
por: Liu, Linbo, et al.
Publicado: (2023)

Vitamin E and Pioglitazone: A Comprehensive Systematic Review of Their Efficacy in Non-alcoholic Fatty Liver Disease
por: Mazhar, Iqra J, et al.
Publicado: (2023)

Comprehensive analysis of endoplasmic reticulum-related and secretome gene expression profiles in the progression of non-alcoholic fatty liver disease
por: Gao, Rong, et al.
Publicado: (2022)

Identification of biomarkers for the diagnosis of chronic kidney disease (CKD) with non-alcoholic fatty liver disease (NAFLD) by bioinformatics analysis and machine learning
por: Cao, Yang, et al.
Publicado: (2023)

Associations of lipid parameters with non-alcoholic fatty liver disease in type 2 diabetic patients according to obesity status and metabolic goal achievement
por: Zhu, Zengzhe, et al.
Publicado: (2022)

How Useful Are Monogenic Rodent Models for the Study of Human Non-Alcoholic Fatty Liver Disease?
por: Mann, Jake P., et al.
Publicado: (2016)

Non-Alcoholic Fatty Liver Disease in Obese Youth With Insulin Resistance and Type 2 Diabetes
por: Scapaticci, Serena, et al.
Publicado: (2021)

Ectodysplasin A Is Increased in Non-Alcoholic Fatty Liver Disease, But Is Not Associated With Type 2 Diabetes
por: Bayliss, Jacqueline, et al.
Publicado: (2021)

Lower Circulating Leptin Levels Are Related to Non-Alcoholic Fatty Liver Disease in Children With Obesity
por: Brandt, Stephanie, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_n41i45pt6bq3mk6rsv6r5lhajn